Drugs / S101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07244380 | Nov 2025 → Sep 2026 overdue | T lymphoblastic leukemia/lymphoma | Hebei Senlang Biotechnology Inc., Ltd. | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2015-12-07 | Allarity Therapeutics | MPI og Mundipharma EDO GmbH indgår aftale om brug af MPI’s DRP(TM) biomarkør til deres førende lægemiddelkandidat EDO-S101 til behandling af kræft i kliniske forsøg allarity.com ↗ |
| 2015-12-07 | Allarity Therapeutics | MPI and Mundipharma EDO GmbH enters agreement of DRP(TM) for their anti cancer lead compound EDO-S101 in clinical trials allarity.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S101 | “A Phase II Clinical Trial of S101 Autologous CAR-T Cell Injection for the Treatment of CD7-Positive Relapsed or Refractory T-Lymphoblastic Lymphoma/Leukemia (T-LBL/ALL).” NCT07244380 ↗ |
| Modality | Cell therapy | “Autologous CD7-targeting CAR T cells” NCT07244380 ↗ |
| Route | Intravenous | “intravenous injection once” NCT07244380 ↗ |
| Target | CD7 | “Autologous CD7-targeting CAR T cells” NCT07244380 ↗ |